Ratio de rendimiento sobre el capital contable (ROE)
desde 2005
Cálculo
Celgene Corp., ROE, tendencias a largo plazocálculo
| ROE | = | 100 | × | Utilidad (pérdida) neta atribuible a Celgene1 | ÷ | Capital contable1 | |
|---|---|---|---|---|---|---|---|
| 31 dic. 2018 | 65.67% | = | 100 | × | 4,046) | ÷ | 6,161) |
| 31 dic. 2017 | 42.48% | = | 100 | × | 2,940) | ÷ | 6,921) |
| 31 dic. 2016 | 30.29% | = | 100 | × | 1,999) | ÷ | 6,599) |
| 31 dic. 2015 | 27.07% | = | 100 | × | 1,602) | ÷ | 5,919) |
| 31 dic. 2014 | 30.65% | = | 100 | × | 2,000) | ÷ | 6,525) |
| 31 dic. 2013 | 25.94% | = | 100 | × | 1,450) | ÷ | 5,590) |
| 31 dic. 2012 | 25.57% | = | 100 | × | 1,456) | ÷ | 5,694) |
| 31 dic. 2011 | 23.91% | = | 100 | × | 1,318) | ÷ | 5,513) |
| 31 dic. 2010 | 14.71% | = | 100 | × | 881) | ÷ | 5,984) |
| 31 dic. 2009 | 17.68% | = | 100 | × | 777) | ÷ | 4,395) |
| 31 dic. 2008 | -43.93% | = | 100 | × | (1,534) | ÷ | 3,491) |
| 31 dic. 2007 | 7.96% | = | 100 | × | 226) | ÷ | 2,844) |
| 31 dic. 2006 | 3.49% | = | 100 | × | 69) | ÷ | 1,976) |
| 31 dic. 2005 | 10.01% | = | 100 | × | 64) | ÷ | 636) |
Basado en los informes: 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
1 US$ en millones
Comparación con la competencia
Celgene Corp., ROE, tendencias a largo plazo, comparación con los competidores
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Zoetis Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 dic. 2018 | 65.67% | — | 67.15% | 35.07% | 9.40% | 32.88% | 25.51% | 25.60% | 23.30% | 17.59% | 27.91% | 10.65% | 65.35% |
| 31 dic. 2017 | 42.48% | 104.16% | 7.84% | 8.58% | 9.45% | -1.76% | 22.64% | 2.16% | 6.97% | 29.47% | 19.51% | 8.76% | 48.81% |
| 31 dic. 2016 | 30.29% | 128.41% | 25.85% | 27.55% | 11.10% | 19.54% | 71.48% | 23.49% | 9.78% | 12.12% | 20.13% | 9.39% | 55.21% |
| 31 dic. 2015 | 27.07% | 130.39% | 24.71% | 10.97% | 14.17% | 16.53% | 97.70% | 21.66% | 9.94% | 10.75% | 17.40% | 9.25% | 31.74% |
| 31 dic. 2014 | 30.65% | 101.84% | 20.01% | 13.49% | 11.11% | 15.55% | 78.45% | 23.40% | 24.50% | 12.81% | 13.69% | 9.22% | 44.47% |
| 31 dic. 2013 | 25.94% | 91.90% | 23.00% | 16.91% | 12.04% | 26.57% | 27.05% | 18.68% | 8.85% | 28.83% | 21.74% | 7.55% | 53.62% |
| 31 dic. 2012 | 25.57% | 156.85% | 22.80% | 14.39% | 12.58% | 27.69% | 27.84% | 16.74% | 11.63% | 17.93% | 60.24% | 7.62% | 10.83% |
| 31 dic. 2011 | 23.91% | — | 19.35% | 23.25% | 12.85% | 32.11% | 41.60% | 16.94% | 11.50% | 12.18% | -45.65% | 8.84% | — |
| 31 dic. 2010 | 14.71% | — | 19.32% | 19.74% | 13.08% | 40.82% | 49.48% | 23.57% | 1.58% | 9.40% | -19.79% | 6.74% | — |
| 31 dic. 2009 | 17.68% | — | 20.32% | 71.49% | 9.90% | 45.45% | 41.40% | 24.25% | 21.85% | 9.59% | -17.10% | 5.51% | — |
| 31 dic. 2008 | -43.93% | — | 20.58% | 42.86% | 13.43% | -30.76% | 48.43% | 30.46% | 41.63% | 14.08% | -19.75% | 6.66% | — |
| 31 dic. 2007 | 7.96% | — | 17.72% | 20.50% | 15.08% | 21.61% | 46.69% | 24.41% | 18.01% | 12.53% | -22.94% | 5.25% | — |
| 31 dic. 2006 | 3.49% | — | 15.56% | 15.86% | 16.89% | 24.25% | -65.54% | 28.11% | 25.25% | 27.10% | -47.24% | 1.21% | — |
| 31 dic. 2005 | 10.01% | — | 17.96% | 26.77% | 17.67% | 18.34% | 26.88% | 27.49% | 25.85% | 12.32% | -83.72% | 7.99% | — |
Basado en los informes: 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
Comparación con el sector industrial: Productos farmacéuticos, biotecnología y ciencias de la vida
Celgene Corp., ROE, tendencias a largo plazo, comparación con el sector industrial: productos farmacéuticos, biotecnología y ciencias de la vida
| Celgene Corp. | Productos farmacéuticos, biotecnología y ciencias de la vida | |
|---|---|---|
| 31 dic. 2018 | 65.67% | 26.26% |
| 31 dic. 2017 | 42.48% | 14.80% |
| 31 dic. 2016 | 30.29% | 22.47% |
| 31 dic. 2015 | 27.07% | 21.72% |
| 31 dic. 2014 | 30.65% | 21.32% |
| 31 dic. 2013 | 25.94% | 20.66% |
| 31 dic. 2012 | 25.57% | 18.26% |
| 31 dic. 2011 | 23.91% | 15.55% |
| 31 dic. 2010 | 14.71% | 14.28% |
| 31 dic. 2009 | 17.68% | 20.65% |
| 31 dic. 2008 | -43.93% | 21.59% |
| 31 dic. 2007 | 7.96% | 17.30% |
| 31 dic. 2006 | 3.49% | 22.03% |
| 31 dic. 2005 | 10.01% | 19.22% |
Basado en los informes: 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
Comparación con la industria: Atención médica
Celgene Corp., ROE, tendencias a largo plazo, comparación con la industria: atención médica
| Celgene Corp. | Atención médica | |
|---|---|---|
| 31 dic. 2018 | 65.67% | 17.64% |
| 31 dic. 2017 | 42.48% | 14.44% |
| 31 dic. 2016 | 30.29% | 18.00% |
| 31 dic. 2015 | 27.07% | 18.21% |
| 31 dic. 2014 | 30.65% | 18.74% |
| 31 dic. 2013 | 25.94% | 18.27% |
| 31 dic. 2012 | 25.57% | 17.42% |
| 31 dic. 2011 | 23.91% | 15.35% |
| 31 dic. 2010 | 14.71% | 14.63% |
| 31 dic. 2009 | 17.68% | 19.52% |
| 31 dic. 2008 | -43.93% | 18.97% |
| 31 dic. 2007 | 7.96% | 17.18% |
| 31 dic. 2006 | 3.49% | 20.41% |
| 31 dic. 2005 | 10.01% | 18.45% |
Basado en los informes: 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).